BRPI0416854B8 - suspensão aquosa estéril de ciclesonida adequada para nebulização, método para sua preparação e uso da dita suspensão, bem como produto farmacêutico - Google Patents

suspensão aquosa estéril de ciclesonida adequada para nebulização, método para sua preparação e uso da dita suspensão, bem como produto farmacêutico

Info

Publication number
BRPI0416854B8
BRPI0416854B8 BRPI0416854A BRPI0416854A BRPI0416854B8 BR PI0416854 B8 BRPI0416854 B8 BR PI0416854B8 BR PI0416854 A BRPI0416854 A BR PI0416854A BR PI0416854 A BRPI0416854 A BR PI0416854A BR PI0416854 B8 BRPI0416854 B8 BR PI0416854B8
Authority
BR
Brazil
Prior art keywords
suspension
nebulization
sterile aqueous
ciclesonide
preparation
Prior art date
Application number
BRPI0416854A
Other languages
English (en)
Portuguese (pt)
Inventor
Brueck-Scheffler Antje
Original Assignee
Astrazeneca Ab
Altana Pharma Ag
Covis Pharma B V
Nycomed Asset Man Gmbh
Nycomed Germany Holding Gmbh
Nycomed Gmbh
Takeda Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34684543&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0416854(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab, Altana Pharma Ag, Covis Pharma B V, Nycomed Asset Man Gmbh, Nycomed Germany Holding Gmbh, Nycomed Gmbh, Takeda Gmbh filed Critical Astrazeneca Ab
Publication of BRPI0416854A publication Critical patent/BRPI0416854A/pt
Publication of BRPI0416854B1 publication Critical patent/BRPI0416854B1/pt
Publication of BRPI0416854B8 publication Critical patent/BRPI0416854B8/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J71/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J71/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005Oxygen-containing hetero ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
BRPI0416854A 2003-12-16 2004-12-15 suspensão aquosa estéril de ciclesonida adequada para nebulização, método para sua preparação e uso da dita suspensão, bem como produto farmacêutico BRPI0416854B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03028848.4 2003-12-16
EP03028848 2003-12-16
PCT/EP2004/053495 WO2005058935A2 (en) 2003-12-16 2004-12-15 Aqueous suspensions of ciclesonide for nebulisation

Publications (3)

Publication Number Publication Date
BRPI0416854A BRPI0416854A (pt) 2007-02-13
BRPI0416854B1 BRPI0416854B1 (pt) 2018-05-02
BRPI0416854B8 true BRPI0416854B8 (pt) 2021-05-25

Family

ID=34684543

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0416854A BRPI0416854B8 (pt) 2003-12-16 2004-12-15 suspensão aquosa estéril de ciclesonida adequada para nebulização, método para sua preparação e uso da dita suspensão, bem como produto farmacêutico

Country Status (21)

Country Link
US (2) US20070117783A1 (https=)
EP (2) EP2319858B1 (https=)
JP (1) JP5001657B2 (https=)
KR (1) KR101086095B1 (https=)
CN (1) CN100513417C (https=)
AR (1) AR046892A1 (https=)
AU (1) AU2004298447B2 (https=)
BR (1) BRPI0416854B8 (https=)
CA (1) CA2549038C (https=)
CO (1) CO5700832A2 (https=)
EA (1) EA012388B1 (https=)
EC (1) ECSP066608A (https=)
IL (1) IL175461A (https=)
MY (1) MY159377A (https=)
NO (1) NO337225B1 (https=)
NZ (1) NZ547217A (https=)
PE (1) PE20050941A1 (https=)
TW (1) TWI350757B (https=)
UA (1) UA87123C2 (https=)
WO (1) WO2005058935A2 (https=)
ZA (1) ZA200603768B (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2022796A1 (en) * 2007-08-07 2009-02-11 Nycomed GmbH Amorphous ciclesonide
US7984792B2 (en) * 2008-03-03 2011-07-26 Rolls-Royce Corporation Lubrication system
WO2010064522A1 (ja) * 2008-12-03 2010-06-10 株式会社Lttバイオファーマ 修飾型スーパーオキサイドジスムターゼ含有吸入剤
CA3004707C (en) 2009-09-02 2022-05-31 Synedgen Inc. Methods and compositions for disrupting biofilm utilizing chitosan-derivative compounds
US10105356B2 (en) 2011-01-31 2018-10-23 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
WO2012106382A1 (en) 2011-01-31 2012-08-09 Genoa Pharmaceuticals, Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
WO2013024036A1 (en) 2011-08-12 2013-02-21 Boehringer Ingelheim Vetmedica Gmbh Funny current (if) inhibitors for use in a method of treating and preventing heart failure in feline
US11007150B2 (en) 2011-08-18 2021-05-18 Covis Pharma Gmbh Pharmaceutical aerosol product for administration by oral or nasal inhalation
WO2013039167A1 (ja) 2011-09-14 2013-03-21 塩野義製薬株式会社 吸入用医薬組成物
LT3473255T (lt) 2012-12-21 2022-03-10 Boehringer Ingelheim Vetmedica Gmbh Farmacinė vaisto forma, apimanti ciklezonidą
BR112015010842B1 (pt) * 2012-12-21 2021-03-30 Boehringer Ingelheim Vetmedica Gmbh Uso da ciclesonida para o tratamento de doença das vias respiratórias em cavalos
AU2015204558B2 (en) 2014-01-10 2020-04-30 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
ES2759247T3 (es) 2014-06-18 2020-05-08 Boehringer Ingelheim Vetmedica Gmbh Antagonistas muscarínicos y combinaciones de estos para el tratamiento de enfermedades de las vías respiratorias en caballos
CA2960998A1 (en) 2014-09-11 2016-03-17 Synedgen, Inc. Compositions and methods of use thereof
KR20180030399A (ko) * 2015-08-05 2018-03-22 다이이찌 산쿄 가부시키가이샤 네뷸라이저용 조성물
CN106692163A (zh) * 2015-11-13 2017-05-24 天津金耀集团有限公司 一种吸入用环索奈德混悬液组合物
WO2019090405A1 (pt) * 2017-11-11 2019-05-16 Carvalho Junior Mario Virgilio De Medicamento de ciclesonida para cura e prevenção da gripe causada pelo vírus influenza
WO2020123336A1 (en) * 2018-12-13 2020-06-18 Qrumpharma Inc. Compositions of bedaquiline, combinations comprising them, processes for their preparation, uses and methods of treatment comprising them
WO2021221656A1 (en) 2020-04-30 2021-11-04 Synedgen, Inc. Compositions and methods of use thereof
US20210346613A1 (en) * 2020-05-05 2021-11-11 Mahesh Kumar KHAITAN Controlled delivery device for treating coronavirus infections and methods thereof
CN115835885B (zh) * 2020-06-23 2025-02-07 广州谷森制药有限公司 包含奥达特罗和布地奈德的药物组合物的制备
WO2022213101A1 (en) * 2021-04-01 2022-10-06 Vitrean Inc. Methods for manufacturing of highly concentrated hydrogels
WO2022231533A1 (en) * 2021-04-29 2022-11-03 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi Process for the preparation of sterilized suspensions for the inhalation by nebulization

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE458986B (sv) * 1985-03-29 1989-05-29 Draco Ab Dosfoerpackning
SE8600632D0 (sv) 1986-02-13 1986-02-13 Kabivitrum Ab Novel pharmaceutical composition
GR1001529B (el) * 1990-09-07 1994-03-31 Elmuquimica Farm Sl Μέ?οδος για την λήψη νέων 21-εστέρων της 16-17-ακετάλης της πρ να-1,4-διενο-3,20-διόνης.
US5346702A (en) * 1992-12-04 1994-09-13 Sterling Winthrop Inc. Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
DK0701565T3 (da) 1993-04-02 1999-07-12 Byk Gulden Lomberg Chem Fab Nye prednisolonderivater
US5540930A (en) * 1993-10-25 1996-07-30 Pharmos Corporation Suspension of loteprednol etabonate for ear, eye, or nose treatment
GB9410222D0 (en) 1994-05-21 1994-07-06 Glaxo Wellcome Australia Ltd Medicaments
DE4440337A1 (de) * 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
DE19541689A1 (de) 1994-11-14 1996-05-15 Byk Gulden Lomberg Chem Fab Kombinationsarzneimittel
DE19635498A1 (de) 1996-09-03 1998-03-26 Byk Gulden Lomberg Chem Fab Verfahren zur Epimerenanreicherung
US6120752A (en) * 1997-05-21 2000-09-19 3M Innovative Properties Company Medicinal aerosol products containing formulations of ciclesonide and related steroids
SE9704186D0 (sv) * 1997-11-14 1997-11-14 Astra Ab New composition of matter
US6598603B1 (en) * 1997-12-31 2003-07-29 Astra Aktiebolag Method for treating respiratory diseases
TWI243687B (en) * 1998-04-21 2005-11-21 Teijin Ltd Pharmaceutical composition for application to mucosa
US6264923B1 (en) 1998-05-13 2001-07-24 3M Innovative Properties Company Medicinal aerosol formulation of ciclesonide and related compounds
KR100635456B1 (ko) 1998-05-29 2006-10-18 스키에파마 캐나다 인코포레이티드 열보호화 마이크로입자 조성물 및 그의 말단의 스팀멸균방법
US6241969B1 (en) * 1998-06-26 2001-06-05 Elan Corporation Plc Aqueous compositions containing corticosteroids for nasal and pulmonary delivery
IT1303692B1 (it) 1998-11-03 2001-02-23 Chiesi Farma Spa Procedimento per la preparazione di sospensioni di particelle difarmaci da somministrare per inalazione.
IT1313553B1 (it) * 1999-07-23 2002-09-09 Chiesi Farma Spa Formulazioni ottimizzate costituite da soluzioni di steroidi dasomministrare per inalazione.
AR026073A1 (es) * 1999-10-20 2002-12-26 Nycomed Gmbh Composicion farmaceutica acuosa que contiene ciclesonida
AR026072A1 (es) * 1999-10-20 2002-12-26 Nycomed Gmbh Composicion farmaceutica que contiene ciclesonida para aplicacion a la mucosa
CA2356177A1 (en) 1999-10-20 2001-04-26 Kazuya Takanashi Aqueous pharmaceutical compositions
DE10062712A1 (de) * 2000-12-15 2002-06-20 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und Corticosteroiden
US20020183292A1 (en) * 2000-10-31 2002-12-05 Michel Pairet Pharmaceutical compositions based on anticholinergics and corticosteroids
BR0115584A (pt) * 2000-11-24 2003-09-23 Breath Ltd Esterilização de produtos farmacêuticos
US20030055026A1 (en) * 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
US6667344B2 (en) * 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
DE10145361A1 (de) * 2001-09-14 2003-04-03 Pari Gmbh Verfahren zur Herstellung von flüssigen, sterilen Zubereitungen zur Inhalation
WO2003035030A1 (en) 2001-10-24 2003-05-01 Pari Gmbh Kit for the preparation of a pharmaceutical composition
WO2003070285A1 (en) 2002-02-19 2003-08-28 Resolution Chemicals Limited Solvent-based sterilisation of pharmaceuticals
WO2003074558A2 (en) 2002-03-04 2003-09-12 Nymox Corporation Spheron components useful in determining compounds capable of treating symptoms of alzheimer's disease, and treatments and animal models produced therefrom
AU2003236093A1 (en) 2002-04-12 2003-10-27 Ajinomoto Co., Inc. Composition for preventing arteriosclerosis
ITMI20020808A1 (it) * 2002-04-17 2003-10-17 Chiesi Farma Spa Procedimento per la preparazione di una sospensione sterile di particelle di beclometasone dipropionato da somministrare per inalazione
JP4364486B2 (ja) 2002-07-02 2009-11-18 帝人株式会社 無菌水性懸濁製剤
EP3513813A1 (en) * 2002-07-02 2019-07-24 Astrazeneca Ciclesonide-containing sterile aqueous suspension
US20040023935A1 (en) * 2002-08-02 2004-02-05 Dey, L.P. Inhalation compositions, methods of use thereof, and process for preparation of same
CA2495830C (en) * 2002-08-30 2012-08-21 Altana Pharma Ag The use of the combination of ciclesonide and antihistamines for the treatment of allergic rhinitis
WO2004029574A1 (ja) 2002-09-24 2004-04-08 Fujitsu Limited 歪み波形制御装置、歪み規制部材、歪み波形制御装置の歪み波形制御方法、及び歪み波形制御プログラム
EP1556091A1 (en) 2002-10-04 2005-07-27 Elan Pharma International Limited Gamma irradiation of solid nanoparticulate active agents
ITMI20022674A1 (it) * 2002-12-18 2004-06-19 Chiesi Farma Spa Procedimento per la preparazione di formulazioni sterili a base di principi attivi farmaceutici cristallini micronizzati da somministrare come sospensioni acquose per inalazione.
EP1454636A1 (en) 2003-03-04 2004-09-08 Dompé S.P.A. Sterilization of glucocorticoid drug particles for pulmonary delivery
MY143936A (en) 2003-03-27 2011-07-29 Nycomed Gmbh Process for preparing crystalline ciclesonide with defined particle size
TWI359675B (en) * 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
PT1670482E (pt) * 2003-09-16 2014-03-12 Takeda Gmbh Utilização de ciclesonida para o tratamento de doenças respiratórias
DE10347994A1 (de) * 2003-10-15 2005-06-16 Pari GmbH Spezialisten für effektive Inhalation Wässrige Aerosol-Zubereitung
DE602005026225D1 (de) 2004-03-12 2011-03-24 Cipla Ltd Sterilisationsprozess für Steroide
GB0410995D0 (en) 2004-05-17 2004-06-23 Norton Healthcare Ltd Heat sterilization of glucocorticosteroids
ITSA20040012A1 (it) 2004-09-07 2004-12-07 Genetec S P A Processo di sterilizzazione di un glucocorticosteroide.
GB0425266D0 (en) 2004-11-16 2004-12-15 Norton Healthcare Ltd Pharmaceutical manufacturing process

Also Published As

Publication number Publication date
IL175461A0 (en) 2006-09-05
TWI350757B (en) 2011-10-21
HK1098486A1 (zh) 2007-07-20
TW200524615A (en) 2005-08-01
UA87123C2 (uk) 2009-06-25
NZ547217A (en) 2009-05-31
NO20063047L (no) 2006-09-05
EP1697398B1 (en) 2012-07-04
PE20050941A1 (es) 2005-11-08
NO337225B1 (no) 2016-02-15
KR20060122890A (ko) 2006-11-30
WO2005058935A2 (en) 2005-06-30
CN100513417C (zh) 2009-07-15
CA2549038A1 (en) 2005-06-30
EP2319858B1 (en) 2017-08-09
ZA200603768B (en) 2007-10-31
CN1890256A (zh) 2007-01-03
EA012388B1 (ru) 2009-10-30
WO2005058935A3 (en) 2006-05-18
AR046892A1 (es) 2005-12-28
AU2004298447A1 (en) 2005-06-30
AU2004298447B2 (en) 2011-04-21
CA2549038C (en) 2014-08-05
BRPI0416854B1 (pt) 2018-05-02
MY159377A (en) 2016-12-30
BRPI0416854A (pt) 2007-02-13
CO5700832A2 (es) 2006-11-30
US20070117783A1 (en) 2007-05-24
JP5001657B2 (ja) 2012-08-15
US11052042B2 (en) 2021-07-06
JP2007513993A (ja) 2007-05-31
EP2319858A1 (en) 2011-05-11
EP1697398A2 (en) 2006-09-06
ECSP066608A (es) 2006-10-25
US20160015634A1 (en) 2016-01-21
EA200601091A1 (ru) 2006-12-29
KR101086095B1 (ko) 2011-11-25
IL175461A (en) 2013-12-31

Similar Documents

Publication Publication Date Title
BRPI0416854B8 (pt) suspensão aquosa estéril de ciclesonida adequada para nebulização, método para sua preparação e uso da dita suspensão, bem como produto farmacêutico
BRPI0416801A (pt) derivados de 1h-imidazoquinolina como inibidores de proteìna sinase
CU23208A3 (es) Oxazolidinonas sustituidas y su uso en el campo de la coagulacion sanguinea
BR0207694A (pt) Composto ou um sal, solvato ou derivado fisiologicamente funcional deste, método para a profilaxia ou tratamento de uma condição clìnica em um mamìfero, formulação farmacêutica, combinação, uso de um composto ou de um sal, solvato ou derivado fisiologicamente funcional deste farmaceuticamente aceitáveis, processo para a preparação de um composto ou de um sal, solvato ou derivado fisiologicamente funcional deste, e, intermediários
ATE381535T1 (de) Phenethanolaminderivate
BRPI0609784B8 (pt) compostos éster de n-alquilcarbonil-aminoácido e n-alquilcarbonil-amino lactona, composição, e, uso de um composto
NO20032111L (no) Nye medikamentblandinger basert pa tiotropium-salter og pa salmeterol-salter
BR0214243A (pt) Derivado de sulfonamida processo para a preparação de um derivado de sulfonamida e seus sais fisiologicamente aceitáveis, composição farmacêutica e uso de um derivado de sulfonamida
BRPI0212455B8 (pt) composto derivado de fenetanolamina para o tratamento de doenças respiratórias, formulação farmacêutica, combinação, e, uso do mesmo
BRPI0416796A (pt) compostos orgánicos
BRPI0210941B8 (pt) produto farmacêutico contendo combinações de oxazolidinonas substituídas, seu uso, seu processo de produção, e medicamento
BRPI0910832B8 (pt) derivados de tienopiridona como ativadores de proteína quinase ativada por amp (ampk), seus usos, seu processo de preparação e seus intermediários, e medicamentos.
BR0111335A (pt) Derivado de quinazolina, processo para a preparação de um derivado de, quinazolina, composição farmacêutica, e, uso de um derivado de quinazolina
BRPI0407253A (pt) Heterociclil-3-sulfonilindazóis como ligandos 5-hidroxitriptamina-6 processo de preparação dos mesmos, seus usos na preparação de uma composição farmacêutica e composição farmacêutica compreendendo os referidos compostos
CN104688648B (zh) 一种口腔用组合物及其制备方法
MXPA06000660A (es) Uso de una composicion cosmetica o farmaceutica que comprende un extracto rico en lupeol, como un ingrediente activo para estimular la sintesis de proteinas de choque termico.
BRPI0511874A (pt) derivados da pirrolopiridina
BR0210473A (pt) Composição compreendendo um inibidor da pde-4 e antagonista do receptor-h1 e seus usos na produção de um medicamento para o tratamento de doenças respiratórias
BRPI0510080A (pt) combinações farmacêuticas contendo benzoxazina para tratar doenças respiratórias
BRPI0414321A (pt) esterilização a alta pressão para esterilização final de preparações farmacêuticas e produtos médicos
BR0209276A (pt) Uso da azitromicina para a preparação de um medicamento para tratamento de doenças inflamatórias não infecciosas
KR20170033925A (ko) 항바이러스 및 세균용 스프레이 조성물
PT1124841E (pt) Fenil-alcenoil-guanidinas processo para a sua preparacao sua utilizacao como medicamentos ou meios de diagnostico bem como composicao farmaceutica que as contem
BRPI0408689B8 (pt) derivados de benzenosulfonamida, método para preparação e utilização disso para o tratamento da dor
BRPI0508177A (pt) composto, processo para a produção do composto, composição farmacêutica, uso do composto método para o tratamento de uma doença e produto de combinação

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: NYCOMED GMBH (DE)

Free format text: ALTERADO DE: ALTANA PHARMA AG

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25D Requested change of name of applicant approved

Owner name: TAKEDA GMBH (DE)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25A Requested transfer of rights approved

Owner name: NYCOMED ASSET MANAGEMENT GMBH (DE)

B25A Requested transfer of rights approved

Owner name: NYCOMED GERMANY HOLDING GMBH (DE)

B25D Requested change of name of applicant approved

Owner name: TAKEDA GMBH (DE)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B25A Requested transfer of rights approved

Owner name: ASTRAZENECA AB (SE)

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B25A Requested transfer of rights approved
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/12/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF